Today United Therapeutics Corporation announced the sale of its Creating Hope Act priority review voucher to AbbVie for $350 million.
United Therapeutics earned the voucher for its development of Unituxin for neuroblastoma, a pediatric cancer.
“In addition to being a stimulus to incentivize other biopharma companies to prioritize pediatric drug development, this additional capital provides United Therapeutics an even greater war chest to seek new development opportunities across the array of pediatric cancers with urgent and high unmet need,” Co-CEO of United Therapeutics, Roger Jeffs said.
This is more proof that the Creating Hope Act can enable companies to develop pediatric cancer drugs and do well by doing good.
Now, we look forward to working with Chairman Alexander, Ranking Member Murray and the Senate HELP Committee to ensure The Advancing Hope Act, S. 1878, and Kids’ Innovative Drugs (KIDS) Initiative are passed as soon as possible.